Anika Schrade

Albert Einstein Allee 11
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Journal: Blood

Published: July 09, 2025

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Journal: Blood

Published: July 09, 2025

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Journal: Blood advances

Published: May 24, 2024

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG).

Journal: HemaSphere

Published: April 12, 2024

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Haematology

Published: February 26, 2023

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.

Journal: Blood advances

Published: February 02, 2022

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.

Journal: Blood advances

Published: June 15, 2020

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.

Journal: Blood

Published: April 06, 2020

Inverse Pickering Emulsions with Droplet Sizes below 500 nm.

Inverse Pickering Emulsions with Droplet Sizes below 500 nm.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: September 09, 2015

Pickering-type stabilized nanoparticles by heterophase polymerization.

Pickering-type stabilized nanoparticles by heterophase polymerization.

Journal: Chemical Society reviews

Published: May 30, 2013

Synthesis and characterization of dually labeled Pickering-type stabilized polymer nanoparticles in a downscaled miniemulsion system.

Synthesis and characterization of dually labeled Pickering-type stabilized polymer nanoparticles in a downscaled miniemulsion system.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: June 14, 2012

Surface roughness and charge influence the uptake of nanoparticles: fluorescently labeled pickering-type versus surfactant-stabilized nanoparticles.

Surface roughness and charge influence the uptake of nanoparticles: fluorescently labeled pickering-type versus surfactant-stabilized nanoparticles.

Journal: Macromolecular bioscience

Published: May 13, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026